Mertiva invests SEK 3.5M in AttgeNO

AttgeNO, a Stockholm, Sweden-based company working on the development of new blood vessel-inducing drugs, announced raising SEK 3.5M ($400k) in capital investment from Mertiva. The deal values the company at SEK 78M ($9M).

AttgeNO is working on the development of new blood vessel-inducing drugs. Supernitro (PDNO) is a new patented drug candidate for the treatment of acute life threatening high blood pressure in the lung, which may occur in conjunction with cardiac surgery and fatal outcome.

With the money taken into the new issue, the plan is that AttgeNO will be able to conduct clinical Phase 1 studies in the next year.